CME vs. Upstart: Which Financial Stock Is a Better Buy for 2027?
CME's roughly $4 billion profit and near-zero leverage stand in contrast to Upstart's 64% revenue surge, but the lending specialist's leverage and negative free cash flow tell a different story.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.